Janssen Demonstrates Strong Commitment to Inflammatory Bowel Disease with Data from 25 Abstracts Presented at the 2019 Digestive Disease Week Annual Meeting
Advertisement
Phase 3 Data Evaluating STELARA® (ustekinumab) Efficacy and Safety in Patients with Moderate to Severe Ulcerative Colitis Featured in Two Oral Presentations